Effects of 1,25(OH)2D3 and vitamin D receptor on peripheral CD4+/CD8+ double-positive T lymphocytes in a mouse model of systemic lupus erythematosus

Journal of Cellular and Molecular Medicine

Volumn 21, Issue 5, 2017, Pages 975-985

  Ding, Yan ^a   Liao, Wang ^b   He, Xiao Jie ^c,d   Xiang, Wei ^a  

^a Department of Dermatology Maternal and Child Health Care Hospital of Hainan Province   (China)

^b HAINAN GENERAL HOSPITAL   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

1,25(OH)2D3; CD4+; CD8+; mouse model; systemic lupus erythematosus; T lymphocytes; vitamin D receptor

Indexed keywords

CALCITRIOL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOFLUORESCENCE TEST; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; WESTERN BLOTTING; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; CALCITRIOL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLUORESCENT ANTIBODY TECHNIQUE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE, INBRED MRL LPR; PHOSPHORYLATION; RECEPTORS, CALCITRIOL; RNA, MESSENGER;

EID: 85008402256     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.13037     Document Type: Article

References (31)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007; 369: 587–96.
2. Ribi C, Trendelenburg M, Gayet-Ageron A, et al. The Swiss systemic lupus erythematosus Cohort Study (SSCS) – cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Med Wkly. 2014; 144: w13990.
3. Li X, Wang Y. Systemic lupus erythematosus with acute inflammatory demyelinatingpolyneuropathy: a case report and review of the literature. J Clin Med Res. 2016; 8: 555–9.
4. Son M, Kim SJ, Diamond B. SLE-associated risk factors affect DC function. Immunol Rev. 2016; 269: 100–17.
5. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010; 6: 683–92.
6. Handono K, Marisa D, Kalim H. Association between the low levels of vitamin D and Treg function in systemic lupus erythematosus patients. Acta Med Indones. 2013; 45: 26–31.
7. Ramos-Martinez E, Villasenor-Cardoso MI, Lopez-Vancell MR, et al. Effect of 1,25(OH)2D3 on BALB/c mice infected with Leishmania mexicana. Exp Parasitol. 2013; 134: 413–21.
8. Wahono CS, Rusmini H, Soelistyoningsih D, et al. Effects of 1,25(OH)2D3 in immune response regulation of systemic lupus erithematosus (SLE) patient with hypovitamin D. Int J Clin Exp Med. 2014; 7: 22–31.
9. Haussler MR, Jurutka PW, Mizwicki M, et al. Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab. 2011; 25: 543–59.
10. Carvalho C, Marinho A, Leal B, et al. Association between vitamin D receptor (VDR) gene polymorphisms and systemic lupus erythematosus in Portuguese patients. Lupus. 2015; 24: 846–53.
11. Orlans FB. Ethical decision making about animal experiments. Ethics Behav. 1997; 7: 163–71.
12. Tuo YL, Li XM, Luo J. Long noncoding RNA UCA1 modulates breast cancer cell growth and apoptosis through decreasing tumor suppressive miR-143. Eur Rev Med Pharmacol Sci. 2015; 19: 3403–11.
13. Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014; 10: 365–73.
14. Szodoray P, Tarr T, Bazso A, et al. The immunopathological role of vitamin D in patients with SLE: data from a single centre registry in Hungary. Scand J Rheumatol. 2011; 40: 122–6.
15. Mok CC, Birmingham DJ, Leung HW, et al. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology (Oxford). 2012; 51: 644–52.
16. Mostowska A, Lianeri M, Wudarski M, et al. Vitamin D receptor gene BsmI, FokI, ApaI and TaqI polymorphisms and the risk of systemic lupus erythematosus. Mol Biol Rep. 2013; 40: 803–10.
17. Singh A, Kamen DL. Potential benefits of vitamin D for patients with systemic lupus erythematosus. Dermatoendocrinol. 2012; 4: 146–51.
18. Boyan BD, Jennings EG, Wang L, et al. Mechanisms regulating differential activation of membrane-mediated signaling by 1alpha,25(oh)2d3 and 24r,25(oh)2d3. J Steroid Biochem Mol Biol. 2004; 89–90: 309–15.
19. Capiati DA, Vazquez G, Tellez Inon MT, et al. Role of protein kinase c in 1,25(oh)(2)-vitamin d(3) modulation of intracellular calcium during development of skeletal muscle cells in culture. J Cell Biochem. 2000; 77: 200–12.
20. Hmama Z, Nandan D, Sly L, et al. 1alpha,25-dihydroxyvitamin d(3)-induced myeloid cell differentiation is regulated by a vitamin d receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med. 1999; 190: 1583–94.
21. Boyan BD, Posner GH, Greising DM, et al. Hybrid structural analogues of 1,25-(oh)2d3 regulate chondrocyte proliferation and proteoglycan production as well as protein kinase c through a nongenomic pathway. J Cell Biochem. 1997; 66: 457–70.
22. Deeb KK, Trump DL, Johnson CS. Vitamin d signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007; 7: 684–700.
23. Chattopadhyay N, MacLeod RJ, Tfelt-Hansen J, et al. 1alpha,25(oh)2-vitamin d3 inhibits hgf synthesis and secretion from mg-63 human osteosarcoma cells. Am J Physiol Endocrinol Metab. 2003; 284: E219–27.
24. Chaiamnuay S, Chailurkit LO, Narongroeknawin P, et al. Current daily glucocorticoid use and serum creatinine levels are associated with lower 25(OH) vitamin D levels in Thai patients with systemic lupus erythematosus. J Clin Rheumatol. 2013; 19: 121–5.
25. Ehrchen J, Helming L, Varga G, et al. Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major. FASEB J. 2007; 21: 3208–18.
26. Shah D, Kiran R, Wanchu A, et al. Relationship between T lymphocyte subsets and cortisol in systemic lupus erythematosus. Kathmandu Univ Med J (KUMJ). 2009; 7: 213–9.
27. Elser B, Lohoff M, Kock S, et al. IFN-gamma represses IL-4 expression via IRF-1 and IRF-2. Immunity. 2002; 17: 703–12.
28. Henriques A, Ines L, Couto M, et al. Frequency and functional activity of Th17, Tc17 and other T-cell subsets in Systemic Lupus Erythematosus. Cell Immunol. 2010; 264: 97–103.
29. Yu Y, Ren XR, Wen F, et al. T-helper-associated cytokines expression by peripheral blood mononuclear cells in patients with polypoidal choroidal vasculopathy and age-related macular degeneration. BMC Ophthalmol. 2016; 16: 80.
30. Dolff S, Quandt D, Wilde B, et al. Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. Arthritis Res Ther. 2010; 12: R150.
31. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009; 60: 1647–56.